Dr. Schwarzschild is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
15 Parkman St
Wac 835 Neurology Associates
Boston, MA 02114Phone+1 617-726-5532Fax+1 617-724-1480
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1991 - 1994- Brigham and Women's HospitalInternship, Internal Medicine, 1990 - 1991
Harvard Medical SchoolClass of 1990
Certifications & Licensure
MA State Medical License 1994 - 2025
PA State Medical License 2001 - 2009- American Board of Psychiatry and Neurology Neurology
Clinical Trials
- Safety of Urate Elevation in Parkinson's Disease Start of enrollment: 2009 Jun 01
- Study of Urate Elevation in Parkinson's Disease, Phase 3 Start of enrollment: 2016 Jun 01
- Assessing Tele-Health Outcomes in Multiyear Extensions of PD Trials Start of enrollment: 2018 Oct 01
Publications & Presentations
PubMed
- 463 citationsA(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in miceJing Chen, Zhihong Huang, Jianya Ma, Jinmin Zhu, Rosario Moratalla
The Journal of Neuroscience. 1999-11-01 - 1040 citationsThe epidemiology of Parkinson's disease: risk factors and preventionAlberto Ascherio, Michael A. Schwarzschild
The Lancet. Neurology. 2016-11-01 - 92 citationsEffect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical TrialMichael A. Schwarzschild, Alberto Ascherio, Cindy Casaceli, Gary C. Curhan, Rebecca Fitzgerald
JAMA. 2021-09-14
Journal Articles
- Efficacy of Nilotinib in Patients with Moderately Advanced Parkinson DiseaseMichael Schwarzschild, MD, JAMA Neurology
Press Mentions
Antioxidant Fails to Slow Parkinson’s Disease Progression in Clinical TrialSeptember 16th, 2021- Antioxidant Therapy Tested in Early Parkinson’sSeptember 14th, 2021
- NSAIDs Reduce LRRK2 Penetrance in Parkinson's DiseaseSeptember 3rd, 2020
- Join now to see all
Grant Support
- Pursuing Purine Pathways To Clinical Trials For Parkinson'S DiseaseNational Institute Of Neurological Disorders And Stroke2009–2012
- Uric Acid:Novel Therapeutic Target For Parkinson'S DiseaseNational Institute Of Neurological Disorders And Stroke2009–2010
- Translational Foundation Of Adenosine Antagonist Use For DyskinesiasNational Institute Of Neurological Disorders And Stroke2006–2010
- Pursuing Purinergic Pathways To Clinical Trials For Parkinson'S DiseaseNational Institute Of Neurological Disorders And Stroke2008
- Targeting Adenosine A2A Receptors In Parkinson'S DiseaseNational Institute Of Neurological Disorders And Stroke2006
- Assess The Efficacy &Safety Of CEP-1347 In PTS W/Early Parkinson'S DiseaseNational Center For Research Resources2004–2006
- A2A Adenosine Receptors In Psychostimulant SensitizationNational Institute On Drug Abuse2001–2005
- Novel Neuroprotection By Caffeine In Parkinson'S DiseaseNational Institute Of Environmental Health Sciences2001–2005
- Translating A2A Receptor Biology Into Novel PD TherapyNational Institute Of Neurological Disorders And Stroke2002
- A2A Adenosine Receptor--A Novel Role In NeuroprotectionNational Institute On Aging2000
- Adenosine A2 Receptors And Psychostimulant InteractionsNational Institute On Drug Abuse1996–1999
- RAS And Neuronal Gene Regulation By CNTFNational Institute Of Neurological Disorders And Stroke1994–1998
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
